Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Defence Therapeutics Inc C.DTC

Alternate Symbol(s):  DTCFF

Healthcare Biotechnology
Defence Therapeutics Inc. is a Canada-based biotechnology company working on engineering vaccines and antibody drug conjugates (ADC) products using its proprietary platform. The Company is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and... see more

Recent & Breaking News (CSE:DTC)

This “vaccine enhancer’s” new patent gives it even wider coverage

Jonathon Brown April 24, 2023

Defence Granted US Patent with Broad Coverage on Accum(TM)-based Vaccine Enhancer Platform Technology

Newsfile April 24, 2023

Defence's Novel Accum(TM)-mRNA Vaccine Now Administered for Testing on Cancer

Newsfile April 17, 2023

RETRANSMISSION: Defence Breakthrough: Successfully Engineered Accum(TM)-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum(TM)-mRNA Cancer Vaccine Program Begins

Newsfile April 11, 2023

Defence Breakthrough: Successfully Engineered Accum(TM)-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum(TM)-mRNA Cancer Vaccine Program Begins

Newsfile April 10, 2023

Defence to Complete a Final Pre-Clinical Study Prior to IND Filings for the AccuTOX(TM) Phase I Cancer Trial at the City of Hope National Medical Center and Beckman Research Institute

Newsfile March 28, 2023

Defence Therapeutics Announces Exercise of Warrants for Gross Proceeds of over $5 Million

Newsfile March 17, 2023

CSE Bulletin: INDEX - CSE 25 INDEX QUARTERLY REBALANCING

Newsfile March 16, 2023

Defence Therapeutics (CSE:DTC) to develop new cancer treatment with nuclear energy group

Caroline Egan  March 14, 2023

Defence Therapeutics Signs Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer

Newsfile March 14, 2023

Defence's Pipeline Advances to Multiple Phase I Clinical Trials

Newsfile February 27, 2023

Defence Delegates City of Hope to Initiate IND Filing for Its AccuTOX(TM) Cancer Program

Newsfile February 21, 2023

RETRANSMISSION: Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors

Newsfile February 6, 2023

Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors

Newsfile February 3, 2023

Defence Therapeutics (CSE:DTC) and CQDM to fund new cancer vaccine platform

Brieanna McCutcheon  February 2, 2023

Defence Therapeutics and CQDM Fund the Development of a New Cancer Vaccine Platform

Newsfile February 2, 2023

Defence's Lung Cancer GLP tox Study on Its Intranasal AccuTOX(TM) Formulation Advances

Newsfile January 31, 2023

Defence's Melanoma Targeted Vaccine A1-Reprogrammed MSC (ARM) Cell Potency Validated

Newsfile January 24, 2023

RETRANSMISSION: Defence to Present at the 9th Annual Immuno-Oncology 360º Summit in New-York February 7-10, 2023

Newsfile January 23, 2023

Defence To Present at The 9th Annual Immuno-Oncology 360 Summit in New-York February 7-10, 2023

Newsfile January 20, 2023